Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer

Prostate Cancer and Prostatic Diseases volume 10, pages 301–306 (2007)Cite this article

Abstract

The metabolic pathways of androgens and processes by which androgens induce re-growth after androgen deprivation therapy in prostate cancer have not been fully elucidated. In this study, finasteride decreased PSA secretion in medium containing testosterone, androstenedione, androstenediol and dehydroepiandrosterone, whereas dihydrotestosterone (DHT)- and hydroxy-flutamide-induced PSA production was not inhibited by finasteride in LNCaP-FGC cells. The present data show that adrenal androgen precursors do not directly interact with androgen receptors (ARs) but are converted to DHT via the intraprostatic metabolic pathways, resulting in the induction of LNCaP activity. This is the first report confirming this mechanism experimentally and also suggest the use of combined therapies that target ARs and prevent the formation of DHT within prostate cancer cells to achieve optimal therapeutic efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Huggins C, Hodges CV . Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.

    CAS  Google Scholar 

  2. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN . Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002; 81: 191–201.

    Article  CAS  PubMed  Google Scholar 

  3. Gregory CW, Johnson Jr RT, Mohler JL, French FS, Wilson EM . Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892–2898.

    CAS  PubMed  Google Scholar 

  4. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC . The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005; 12: 511–532.

    Article  CAS  PubMed  Google Scholar 

  5. Gioeli D et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002; 277: 29304–29314.

    Article  CAS  PubMed  Google Scholar 

  6. Tremblay A, Tremblay GB, Labrie F, Giguère V . Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell 1999; 3: 513–519.

    Article  CAS  PubMed  Google Scholar 

  7. Kato S et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270: 1491–1494.

    Article  CAS  PubMed  Google Scholar 

  8. Vihko P et al. Control of cell proliferation by steroids: the role of 17HSDs. Mol Cell Endocrinol 2006; 241: 141–148.

    Article  Google Scholar 

  9. Tomita Y, Bilim V, Hara N, Kasahara T, Takahashi K . Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer 2003; 104: 400–408.

    Article  CAS  PubMed  Google Scholar 

  10. Berns EM, de Boer W, Mulder E . Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 1986; 9: 247–259.

    Article  CAS  PubMed  Google Scholar 

  11. van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH . The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 1991; 40: 207–214.

    Article  CAS  PubMed  Google Scholar 

  12. Soronen P et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 281–286.

    Article  CAS  PubMed  Google Scholar 

  13. Pelletier G, Luu-The V, Li S, Labrie F . Localization of type 5 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. Cell Tissue Res 2005; 320: 393–398.

    Article  CAS  PubMed  Google Scholar 

  14. Elo JP et al. Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. Int J Cancer 1996; 66: 37–41.

    Article  CAS  PubMed  Google Scholar 

  15. Koh E, Noda T, Kanaya J, Namiki M . Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 2002; 53: 154–159.

    Article  CAS  PubMed  Google Scholar 

  16. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS . Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004; 58: 130–144.

    Article  CAS  PubMed  Google Scholar 

  17. Bonkhoff H, Stein U, Aumuller G, Remberger K . Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996; 29: 261–271.

    Article  CAS  PubMed  Google Scholar 

  18. Thomas LN et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005; 63: 231–239.

    Article  CAS  PubMed  Google Scholar 

  19. Negri-Cesi P et al. Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 1998; 34: 283–291.

    Article  CAS  PubMed  Google Scholar 

  20. Tian G . In vivo time-dependent inhibition of human steroid 5 alpha-reductase by finasteride. J Pharm Sci 1996; 85: 106–111.

    Article  CAS  PubMed  Google Scholar 

  21. Nishiyama T, Hashimoto Y, Takahashi K . The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research 2004; 10: 7121–7126.

    Article  CAS  PubMed  Google Scholar 

  22. Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD . Enzymes of androgen formation and degradation in the human prostate. Ann NY Acad Sci 1990; 595: 53–66.

    Article  CAS  PubMed  Google Scholar 

  23. Culig Z et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541–1550.

    CAS  PubMed  Google Scholar 

  24. Palmberg C et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 1992–1995.

    Article  CAS  PubMed  Google Scholar 

  25. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A . Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 265–271.

    Article  CAS  PubMed  Google Scholar 

  26. Labrie F, Dupont A, Bélanger A . Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S. et Rosenberg SA (eds). Important Advances in Oncology. J.B. Lippincott: Philadelphia, 1985; pp 193–217.

    Google Scholar 

  27. Prostate Cancer Triallists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491–1498.

  28. Labrie F et al. GnRH agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361–379.

    Article  CAS  PubMed  Google Scholar 

  29. Bennett CL et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using Flutamide. Prostate Cancer Prostatic Dis 1999; 2: 4–8.

    Article  CAS  PubMed  Google Scholar 

  30. Akaza H et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004; 34: 20–28.

    Article  PubMed  Google Scholar 

  31. McConnell JD et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–508.

    CAS  PubMed  Google Scholar 

  32. Thompson IM et al. The influence of finasteride on the development of prostate cancer. New England J Med 2003; 349: 215–224.

    Article  CAS  Google Scholar 

  33. Leibowitz RL, Tucker SJ . Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001; 6: 177–182.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Regenerative and Transplant Medicine, Course of Biological Function and Medicine Control, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan

    K Suzuki, T Nishiyama, N Hara, K Yamana & K Takahashi

  2. Laboratory of Molecular Endocrinology and Oncology, Laval University Hospital Research Center (CRCHUL) and Laval University, Quebec City, Quebec, Canada

    F Labrie

Authors
  1. K Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Yamana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Suzuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suzuki, K., Nishiyama, T., Hara, N. et al. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis 10, 301–306 (2007). https://doi.org/10.1038/sj.pcan.4500956

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500956

Keywords

This article is cited by

Search

Advanced search

Quick links